65,437 trials
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 4; 1; 0; 0 Participants
Heart Failure With Preserved Ejection Fraction
Primary: KCCQ-12 — 47; 39 units on a scale
Dizziness Chronic · Vertigo, Peripheral · Fall
Primary: Visual Vertigo Analog Scale (VVAS) — 43.05; 36.84; 31.28; 21.41 score on a scale — p=0.027
Multiple Myeloma
Primary: Change in Diarrhea as Assessed Per CTCAE v5.0 — 0.00; 0.13; 0.00; 0.13 CTCAE grade
Metastatic Triple Negative Breast Cancer
Primary: Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients…
Zika Virus Infection · Adherence, Patient
Primary: Number of Participants With Adherence to Pediatric Zika Care — 14; 15 Participants
Surgical Skin Preparation
Primary: Number of Subjects With Plasma Levels of Chlorexidine Following Systemic Exposure After a Single Topical Application of CHG. — 0; 0; 0 Participants
Plaque Psoriasis
Primary: PASI Percent Change From Baseline to Week 12 — 81.92; 81.91 Percent Change in PASI score
Alcohol Use Disorder
Primary: Percent Drinking Days — 38.5; 46.6; 53 percentage of drinking days — p=0.009
Recurrent Bladder Urothelial Carcinoma · Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
Primary: Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS) — 27 percentage of participants
Burnout, Student · Alcohol; Harmful Use · Quality of Life
Primary: Burnout Change — 0.06; 0.05 change in score on a scale — p=0.482314
Healthy · Male
Primary: Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Zanubrutinib — 2700; 1530 h*ng/mL
Malaria
Primary: Arm A Pharmacokinetic Parameters of Metoprolol & α-hydroxymetoprolol: Area Under Curve (AUC)0-t, AUC0-∞ — 685; 746; 895; 958 ng.h/ml
Testosterone Deficiency
Primary: Patient Satisfaction as Measured by TSQM-9 (Global Satisfaction Domain) — 66.7; 83.1; 83.7 score on a scale
Severely Immunocompromised HIV Patients
Primary: Early Mortality — 9; 13 Participants